GSK Exercises Option on OXB LentiVector Patents

RNS Number : 6411D
Oxford Biomedica PLC
28 October 2015
 

 

 

 

 

 

 

GSK Exercises Option on Oxford BioMedica's LentiVector® Technology Patents

 

Oxford, UK - 28 October 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents.  This follows an agreement signed between GSK and the Group in December 2013.

 

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: "This news further underlines the growing importance and demand for Oxford BioMedica's leading technology and IP.  We are pleased that GSK are using our unique lentiviral vector platform and hope they can rapidly advance the development of new treatments that will benefit patients suffering from rare orphan indications for whom current treatment options are limited."

 

 

- Ends -

 

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

 

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCZMMZGFNDGKZZ